An Antibiotic Regimen for the Treatment of Active Crohn's Disease: A Randomized, Controlled Clinical Trial of Metronidazole plus Ciprofloxacin

Prantera, C.; Zannoni, F.; Scribano, Maria Lia; Berto, Eva; Andreoli, A.; Kohn, Anna; Luzi, C.
February 1996
American Journal of Gastroenterology;Feb1996, Vol. 91 Issue 2, p328
Academic Journal
Objectives: Bacteria in the gut lumen may play a role in the etiology and/or the symptoms of Crohn's disease (CD). Although various antibacterial drugs have been employed in clinical practice, few controlled trials have been conducted, and those had conflicting results. The aim of this study was to investigate the efficacy and the safety of a combination of metronidazole and ciprofloxacin, compared with methylprednisolone, in treating 41 consecutive patients with active CD. Methods: Eligible patients, 13 men and 28 women, mean age 38 yr, were randomly allocated to receive, for 12 wk, ciprofloxacin 500 mg twice daily plus metronidazole 250 mg four times daily or methylprednisolone 0.7-1 mg/kg/day, with variable tapering to 40 mg, followed by tapering of 4 mg weekly. Results: Ten of the 22 antibiotic patients (45.5 %) and 12 of the 19 steroid patients (63%) obtained clinical remission (Crohn's Disease Activity Index ≤ 150) at the end of the 12-wk study (p = NS). Five patients on antibiotics (22.7%) and five patients on steroids (26.3%) were considered treatment failures because of deterioration or persistent symptoms. Six patients receiving antibiotics (27.3%) and two on steroids (10.6%) were withdrawn from the trial because of side effects. One patient on antibiotics was not compliant. Conclusions: metronidazole and ciprofloxacin could be an alternative to steroids in treating the acute phase of CD.


Related Articles

  • Redhill to Start Phase III of Antibiotic Therapy in Crohn's. Sheridan, Cormac // BioWorld International;8/21/2013, Vol. 18 Issue 34, p1 

    The article discusses the start of a Phase III trial of RHB-104 antibiotic for the treatment of Crohn's disease by Redhill Biopharma Ltd. in 2013. To be participated in by 600 patients in North America, Israel and Europe, the trial will involve a single-dose formulation of rifabutin,...

  • Redhill to Start Phase III Trial Of Antibiotic Therapy in Crohn's. Sheridan, Cormac // BioWorld Today;8/21/2013, Vol. 24 Issue 160, p1 

    The article reports on a Phase III trial planned by biopharmaceutical firm Redhill Biopharma Ltd. for RHB-104, an antibiotic treatment for Crohn's disease. The firm will initiate a placebo-controlled Phase III Trial involving 240 patients in North America and Israel, and shortly afterward, a...

  • Phase II antisense sets Crohn disease precedents. Mullard, Asher // Nature Reviews Drug Discovery;May2015, Vol. 14 Issue 5, p301 

    The article discusses the Phase II clinical trial data of mongersen, an experimental drug for the treatment of Crohn disease from pharmaceutical company Celgene, and mentioned the statement of gastroenterologist Séverine Vermeire on the clinical effects of the drug.

  • Die Therapie des komplizierten Morbus Crohn. Scharl, Michael; Barthel, Christiane; Rogler, Gerhard // Praxis (16618157);3/12/2014, Vol. 103 Issue 6, p323 

    During their disease course, the majority of Crohn's disease patients will develop a complicated disease which is characterized by the occurrence of fistulas and/or stenosis. Symptomatic, perianal fistulas should be surgically drained before anti-inflammatory therapy will be initiated....

  • Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review. Al-Omari, Awad; William Cameron, D.; Craig Lee; Corrales-Medina, Vicente F. // BMC Infectious Diseases;2014, Vol. 14 Issue 1, p1 

    Background: The role of oral antibiotic therapy in treating infective endocarditis (IE) is not well established. Methods: We searched MEDLINE, EMBASE and Scopus for studies in which oral antibiotic therapy was used for the treatment of IE. Results: Seven observational studies evaluating the use...

  • Long-Term Antibiotic Treatment for Crohn's Disease: Systematic Review and Meta-Analysis of Placebo- Controlled Trials. Feller, Martin; Huwiler, Karin; Schoepfer, Alain; Shang, Aijing; Furrer, Hansjakob; Egger, Matthias // Clinical Infectious Diseases;2/15/2010, Vol. 50 Issue 4, p473 

    Background. We investigated the effectiveness of long-term antibiotic treatment in patients with Crohn's disease. Methods. We performed a systematic review and meta-analysis of randomized clinical trials. Data sources were Medline (from 1966 through June 2009), EMBASE (from 1980 through June...

  • Focus on infliximab: A TNF-alpha inhibitor that reduces intestinal inflammation in Crohn's disease refractory to conventional therapy. Canada, Todd // Formulary;Dec98, Vol. 33 Issue 12, p1171 

    Reports on the results of clinical trials comparing infliximab, a chimeric anti-tumor necrosis factor-alpha antibody, with placebo in patients with Crohn's disease. Anti-inflammatory effects in patients with Crohn's disease; Rapid clinical responses and disease remission; Significant efficacy...

  • FINANCINGS.  // BioWorld Today;11/8/2013, Vol. 24 Issue 216, p9 

    The article reports on the announcement by biotechnology firm Coronado Biosciences Inc. in November 2013 that a second interim analysis of data was carried out from a trial in 240 patients who had received treatment with Trichuris suis ova in a Phase II trial in Crohn's disease.

  • PHARMA: CLINIC ROUNDUP.  // BioWorld Today;1/9/2014, Vol. 25 Issue 6, p12 

    The article offers information on Phase III trials of vedolizumab drug from Takeda Pharmaceutical Co. Ltd. for the treatment of Crohn's disease and ulcerative colitis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics